Should You Buy Context Therapeutics Inc (CNTX) Stock After it Is Down 6.47% in a Week?

Context Therapeutics Inc (CNTX) stock is lower by 6.47% over the past week and gets a Neutral rating from InvestorsObserver Sentiment Indicator.

Context Therapeutics Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on CNTX!

See Full CNTX Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With CNTX Stock Today?

Context Therapeutics Inc (CNTX) stock is down -2.26% while the S&P 500 has gained 0.87% as of 11:08 AM on Tuesday, Oct 10. CNTX is down -$0.03 from the previous closing price of $1.33 on volume of 4,489 shares. Over the past year the S&P 500 has gained 21.07% while CNTX has gained 14.04%. CNTX lost -$1.17 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Context Therapeutics Inc click here.

More About Context Therapeutics Inc

Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. Click Here to get the full Stock Report for Context Therapeutics Inc stock.